Background: Myxoid Leiomyosarcoma (LMS) is a rare and aggressive subtype of soft tissue sarcoma. Currently the true incidence and prognosis of myxoid leiomyosarcoma is unknown. This study examines several epidemiologic factors associated with patients diagnosed with myxoid LMS utilizing the National Cancer Database (NCDB).

Methods: There were 485 patients diagnosed with myxoid LMS in the NCDB from 2004-2014. Kaplan-Meier analyses were used to estimate 5-year survival, and log-rank tests were used to compare survival amongst stage.

Results: Median age at diagnosis for Myxoid LMS was 54 years. 82.5% of patients were female and 17.5% were male. 76.1% of cases were in Caucasian patients and 56.1% were located in female reproductive tract. The most common pathologic stage was Stage I (16.3%) and 13.9% of patients had metastases present at the time of diagnosis. Treatment involved surgery in 89.5%, 37% received chemotherapy and 26.8% received radiation. Overall median survival was 74.5 months. Average 5-year survival rates for Stages I and II based on NCDB Analytic Stage were 68% and 62%, respectively, while the 5-year survival rate for Stage IV was 18.6%.

Conclusion: This study found myxoid leiomyosarcoma was most common in Caucasian females with a median age at diagnosis of 54 and occurring most commonly in the uterus. 5-year survival was much worse at Stage IV compared to stages I and II.

Vincristine, ifosfamide, doxorubicin and etoposide (VIDE) is an intensive multiagent induction chemotherapy regimen used in the treatment of Ewing and other sarcoma, most often in children and younger adolescents. Its safety and tolerability in Adolescent and Young Adult (AYA) patients is not well documented. VIDE in this setting is novel, with only two Australian non-paediatric institutions adopting its use. This study aims to describe the experience of treating AYA sarcoma patients with VIDE at one of these two institutions, including an assessment of treatment-related adverse effects. Data from all sarcoma patients treated at Royal Prince Alfred Hospital and subsequently Chris O’Brien Lifehouse from 2013 to 2017 were analysed retrospectively. Assessment of VIDE administration, toxicity, and hospital length of stay was made from review of prescribing charts, medical records, and pathology results during treatment. Over this period, 13 patients aged 16 to 43 were treated with 74 cycles of VIDE. The most common toxicities were neutropenia (42%), anaemia (24%) and febrile neutropenia (41%). Dose modification occurred in 64% of cycles. No treatment-related deaths occurred. Even in patients subsequently admitted with febrile neutropenia, median total length of inpatient stay per cycle was 7 nights. VIDE chemotherapy in the AYA population is associated with frequent haematologic adverse events but acceptable tolerability and safety. Our experience demonstrates the feasibility of treating patients with VIDE in an adult oncology institution.

Soft tissue sarcomas (Sts) are rare tumors that make up about 1% of malignant neoplasms. In addition to their histological diversity, Stscan occur anywhere on the body but present predominance in end areas. We aim to describe a case of soft tissue sarcoma because it is a rare malignant neoplasm. We report the case of a male patient, 60 years old, with a previous history of lung adenocarcinoma that started with diffuse abdominal pain with progressive worsening requiring surgical approach presenting histopathological findings compatible with malignant solitary fibrous tumor. He underwent adjuvant chemotherapy but evolved with disease progression. Another surgical approach was performed but due to the extension of the disease, complete resection was not possible and local IMRT radiotherapy was then chosen. The patient has been in clinical follow-up since 2015 considering that the disease has been presenting a slight reduction in its size in the imaging studies.